Brachytherapy
Volume 6, Issue 1 , Pages 34-37 , January 2007

American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103

  • Mark J. Rivard

      Affiliations

    • Departments of Radiation Oncology and Medical Physics, Tufts-New England Medical Center, Boston, MA
    • Corresponding Author InformationCorresponding author. Tufts-New England Medical Center, Radiation Oncology, Medical Physics, #246, 750 Washington Street, Boston, MA 02111, USA. Tel.: +1-617-636-1680; fax: +1-617-636-7621.
    • ,
  • Wayne M. Butler

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Phillip M. Devlin

      Affiliations

    • Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA
    • ,
  • John K. Hayes Jr.

      Affiliations

    • GammaWest Brachytherapy, Salt Lake City, UT
    • ,
  • Robert A. Hearn

      Affiliations

    • Theragenics Corporation, Buford, GA
    • ,
  • Eugene P. Lief

      Affiliations

    • Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY
    • ,
  • Ali S. Meigooni

      Affiliations

    • Department of Radiation Medicine, University of Kentucky, Lexington, KY
    • ,
  • Gregory S. Merrick

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Jeffrey F. Williamson

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia, Richmond, VA

Received 31 August 2006 ,Revised 28 October 2006 ,Accepted 7 November 2006.

References 

  1. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  2. Beyer D, Nath R, Butler W, et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for 103palladium brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:273–275
  3. Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM task group No. 43 report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31:633–674
  4. Williamson JF, Butler WM, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 Task Group 43 Report on dose specification for 103Pd and 125I Interstitial brachytherapy. Med Phys. 2005;32:1424–1439
  5. Williamson JF, Coursey BM, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: Implications for dose specification and prescription (AAPM Report No. 69). Med Phys. 2000;27:634–642
  6. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22:209–234
  7. Williamson JF, Coursey BM, DeWerd LA, et al. Guidance to users of Nycomed Amersham and North American Scientific, Inc. I-125 Interstitial Sources: Dosimetry and calibration changes: Recommendation of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry. Med Phys. 1999;26:570–573
  8. Seltzer SM, Lamperti PJ, Loevinger R, et al. New national air-kerma-strength standards for 125I and 103Pd brachytherapy seeds. J Res Natl Inst Stand Technol. 2003;108:337–358
  9. Nath R, Yue N, Shahnazi K, Bongiorni P. Measurement of dose-rate constant for 103Pd seeds with air kerma strength calibration based upon a primary national standard. Med Phys. 2000;27:655–658
  10. Merrick GS, Wallner KE, Butler WM. Minimizing prostate brachytherapy-related morbidity. Urology. 2003;62:786–792
  11. Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol. 2001;165:436–439
  12. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465–471
  13. Merrick GS, Butler WM, Waller KE, et al. Variability of prostate preimplant dosimetry: A multi-institutional analysis. Brachytherapy. 2005;4:241–251
  14. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125Iodine brachytherapy of prostate cancer. J Urol. 2005;173:803–807
  15. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  16. Wallner K, Merrick G, True L, et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297–1303
  17. Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839–850
  18. Potters L, Morgenstern , Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  19. Sharkey J, Cantor A, Solc Z, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: A 12-year experience from a single group practice. Brachytherapy. 2005;4:34–44
  20. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: Influence of prostatic acid phosphatase. Cancer. 2003;97:979–983
  21. Nath R, Anderson LL, Meli JA, et al. Code of practice for brachytherapy physics: Report of the AAPM Radiation Therapy Committee Task Group No. 56. Med Phys. 1997;24:1557–1598
  22. Minniti R, Chen-Mayer H, Seltzer SM, et al. The US radiation dosimetry standards for 60Co therapy level beams, and the transfer to the AAPM accredited dosimetry calibration laboratories. Med Phys. 2006;33:1074–1077

 The following authors have received financial support from Theragenics Corporation: PMD, RAH, JFW.

PII: S1538-4721(06)00276-5

doi: 10.1016/j.brachy.2006.11.001

Brachytherapy
Volume 6, Issue 1 , Pages 34-37 , January 2007

Article Tools